Sigilon Therapeutics lands Series B
Sigilon Therapeutics Inc, a biotechnology company developing functional cures for patients with chronic diseases, has raised US$80.3 million in Series B financing.
Sigilon Therapeutics Inc, a biotechnology company developing functional cures for patients with chronic diseases, has raised US$80.3 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination
